<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 10:58:58 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>
      BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business
      Update - BridgeBio
    </title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta
      property="og:title"
      content="BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update - BridgeBio"
    />
    <meta
      property="og:description"
      content="&#8211; Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congress, demonstrating that patients survived more and were hospitalized less than has been seen in other interventional studies of transthyretin amyloid cardiomyopathy (ATTR-CM) to the Company’s knowledge, including real-world evidence presented at recent cardiology medical [&hellip;]"
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2023-11-02T11:30:41+00:00"
    />
    <meta
      property="article:modified_time"
      content="2023-11-02T11:52:27+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2023/11/Q3-Graph-1.jpg"
    />
    <meta name="author" content="Holly Condon" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Holly Condon" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="17 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/",
            "url": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/",
            "name": "BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update - BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "primaryImageOfPage": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/#primaryimage"
            },
            "image": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/#primaryimage"
            },
            "thumbnailUrl": "http://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-1.jpeg",
            "datePublished": "2023-11-02T11:30:41+00:00",
            "dateModified": "2023-11-02T11:52:27+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca"
            },
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/"
                ]
              }
            ]
          },
          {
            "@type": "ImageObject",
            "inLanguage": "en-US",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/#primaryimage",
            "url": "https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-1.jpeg",
            "contentUrl": "https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-1.jpeg",
            "width": 1384,
            "height": 893
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update"
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca",
            "name": "Holly Condon",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "caption": "Holly Condon"
            },
            "url": "https://bridgebio.com/author/hcondon/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/stylec89c.css?ver=1734514740"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-cssc89c.css?ver=1734514740"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrustc89c.css?ver=1734514740"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scriptsc89c.js?ver=1734514740"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modalc89c.js?ver=1734514740"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/6119.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../index02b4.html?p=6119" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embed9f47.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embedf27b?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-reports-third-quarter-2023-financial-results-and-business-update%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-6119 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Pharma Reports Third Quarter 2023 Financial Results and
              Business Update
            </h1>
            <section>
              <p align="center">
                <em
                  >&#8211; Presented detailed positive results from the
                  ATTRibute-CM Phase 3 study of acoramidis at the European
                  Society of Cardiology (ESC) Congress, demonstrating that
                  patients survived more and were hospitalized less than has
                  been seen in other interventional studies of transthyretin
                  amyloid cardiomyopathy (ATTR-CM) to the Company’s knowledge,
                  including real-world evidence presented at recent cardiology
                  medical meetings</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; The ATTRibute-CM data presented at ESC also
                  demonstrated proportions of improvement in the treated
                  population on 6-minute walk distance and NT-proBNP greater
                  than observed in prior interventional studies of ATTR-CM to
                  the Company’s knowledge; these results support a
                  differentiated profile for acoramidis in the contemporary care
                  of ATTR-CM</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; A New Drug Application (NDA) for acoramidis is
                  expected to be filed with the U.S. Food and Drug
                  Administration (FDA) by the end of 2023; if approved, this
                  would make acoramidis the next treatment option available to
                  patients with ATTR-CM</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Held positive regulatory meetings with the FDA and
                  the European Medicines Agency (EMA) on the path for
                  infigratinib in children with achondroplasia; reached
                  alignment on a single pivotal one-year, randomized,
                  placebo-controlled Phase 3 clinical trial, clearing the path
                  for the expected initiation of the trial by the end of
                  2023</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Shared data from Phase 2 trial of BBP-418 in patients
                  with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) at
                  the Annual Congress of World Muscle Society, which showed that
                  early changes in glycosylated alpha-dystroglycan (</em
                >α<em
                  >DG) levels predicted subsequent ambulatory improvements,
                  supporting the validity of glycosylated αDG as a potential
                  surrogate endpoint for Accelerated Approval in FORTIFY, the
                  ongoing Phase 3 study of BBP-418 in LGMD2I/R9</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Published Phase 2b trial data of encaleret in
                  patients with autosomal dominant hypocalcemia type 1 (ADH1) in
                  the New England Journal of Medicine; results demonstrated
                  rapid and sustained restoration of physiologic mineral
                  homeostasis in all 13 participants with ADH1; registrational
                  Phase 3 trial CALIBRATE is ongoing with announcement of
                  topline results expected in 2024</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Phase 1/2 trial of BBP-631 for treatment of
                  congenital adrenal hyperplasia (CAH) is ongoing with the
                  dose-escalation portion fully enrolled; Company expects to
                  share data from the study in early 2024</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Three lead KRAS programs are advancing;
                  first-in-class direct KRAS</em
                ><sup><em>G12C </em></sup
                ><em
                  >(ON) inhibitor BBO-8520, whose novel direct KRAS (ON)
                  targeting mechanism was observed to be potentially superior to
                  KRAS (OFF) as presented at the recent Triple Meeting, remains
                  on track for an Investigational New Drug (IND) application in
                  2023; PI3Kα:RAS breaker candidate BBO-10203 and pan-KRAS
                  program remain on track for IND and DC nomination,
                  respectively, in 2024</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Signed a multi-year partnership with National
                  Resilience, Inc. (Resilience) to advance BBP-631, BBP-812 and
                  future gene therapy treatments; the deal is intended to reduce
                  manufacturing costs, which have historically been
                  approximately 50%-60% of the Gene Therapy budget, and is
                  expected to help the Company expedite development of gene
                  therapies going forward</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Raised gross proceeds of approximately $316 million
                  via at-the-market (ATM) facility and a private placement
                  equity financing (PIPE) from a syndicate of the largest
                  investment management firms as detailed in the forthcoming S-3
                  filing</em
                >
              </p>
              <p align="center">
                <em
                  >&#8211; Ended the third quarter with $522 million in cash,
                  cash equivalents, and short-term restricted cash, and $38
                  million of investments in equity securities</em
                >
              </p>
              <p>
                <strong
                  >PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE)</strong
                >
                &#8212;  BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the
                Company), a commercial-stage biopharmaceutical company focused
                on genetic diseases and cancers, today reported its financial
                results for the third quarter ended September 30, 2023, and
                provided an update on the Company’s operations.
              </p>
              <p>
                “We continue to be extremely grateful to the patient and
                physician communities with whom we collaborate; their
                partnership has helped us to realize tremendous advancement
                recently across the programs that make up our portfolio,” said
                Neil Kumar, Ph.D., founder and CEO of BridgeBio. “We are excited
                about the progress from our late-stage pipeline, and have begun
                to highlight areas of differentiation for the upcoming,
                potentially blockbuster launch of our ATTR-CM asset. In
                particular, recent real-world evidence on ATTR-CM therapies
                presented at the HFSA scientific sessions suggests that the
                survival levels observed on acoramidis treatment in our Phase 3
                study are indeed differentiated even in the context of the
                contemporary care setting as compared to other agents in the
                field. This continues to reinforce our hypothesis that better
                stabilization leads to better outcomes for patients with
                ATTR-CM.”
              </p>
              <p><strong>BridgeBio’s key programs:</strong></p>
              <ul type="disc">
                <li>
                  <strong
                    >Acoramidis (AG10) – Transthyretin (TTR) stabilizer for
                    transthyretin amyloid cardiomyopathy (ATTR-CM):</strong
                  >
                  <ul type="circle">
                    <li>
                      In August 2023, the Company presented detailed positive
                      results from its Phase 3 ATTRibute-CM study of acoramidis
                      for patients with ATTR-CM; a highly statistically
                      significant result was observed on the primary endpoint
                      with a Win Ratio of 1.8 (p&lt;0.0001). This primary
                      endpoint result consistently favored acoramidis treatment
                      across key subgroups, including National Amyloidosis
                      Center (NAC) ATTR stage I, II, and III patients.
                    </li>
                    <li>
                      Absolute values observed across all-cause mortality (ACM),
                      cardiovascular mortality (CVM) and CVH showed that over 30
                      months, patients survived more and were hospitalized less
                      than has been seen in prior interventional studies of
                      ATTR-CM to the Company’s knowledge, including real-world
                      evidence presented at recent cardiology medical meetings.
                    </li>
                    <li>
                      The 81% survival rate on acoramidis approaches the
                      survival rate in the age-matched U.S. database (~85%); the
                      0.29 mean annual CVH rate on acoramidis approaches the
                      annual hospitalization rate observed in the broader U.S.
                      Medicare population (~0.26).
                    </li>
                    <li>
                      Assessment of measures of disease progression in the trial
                      suggest that on acoramidis, 45% of subjects experienced an
                      improvement from baseline in N-terminal prohormone of
                      brain natriuretic peptide (NT-proBNP) versus 9% on
                      placebo, and 40% of subjects experienced an improvement
                      from baseline on 6-minute walk distance (6MWD) versus 24%
                      on placebo. To the Company’s knowledge, the proportions of
                      treated patients improving on these measures over 30
                      months are higher than have been observed in prior
                      controlled studies in ATTR-CM.
                    </li>
                    <li>
                      We believe these points of differentiation observed in the
                      ATTRibute-CM results are made possible by acoramidis
                      achieving near-complete stabilization of transthyretin
                      (TTR) in both wild-type and variant ATTR patients; serum
                      TTR was promptly and consistently elevated throughout the
                      study.
                    </li>
                    <li>
                      In an exploratory post-hoc analysis of the relationship
                      between on-treatment serum TTR levels and on-treatment
                      measures of CVH, NT-proBNP, and Kansas City Cardiomyopathy
                      Questionnaire (KCCQ), there was an association between the
                      mean on-treatment TTR level and each of these three
                      variables, consistent with the premise that higher degrees
                      of stabilization lead to better outcomes for patients.
                    </li>
                    <li>
                      Acoramidis was well-tolerated with no safety signals of
                      potential clinical concern identified.
                    </li>
                    <li>
                      The Company intends to file an NDA for acoramidis with the
                      FDA by the end of 2023 and marketing authorization
                      applications with additional regulatory authorities
                      globally in 2024.
                    </li>
                    <li>
                      Additional detailed results of ATTRibute-CM are planned
                      for presentation at the American Heart Association
                      Scientific Sessions and the American College of Cardiology
                      Scientific Sessions.
                    </li>
                  </ul>
                </li>
                <li>
                  <strong
                    >Low-dose infigratinib – FGFR1-3 inhibitor for
                    achondroplasia and hypochondroplasia:</strong
                  >
                  <ul type="circle">
                    <li>
                      In September 2023, the Company completed positive
                      regulatory meetings with the FDA and the EMA. Alignment
                      from the FDA and EMA was reached on the adequacy of a
                      one-year, 2:1 randomized, placebo-controlled Phase 3
                      pivotal trial for infigratinib to support a marketing
                      application for the treatment of children with
                      achondroplasia.
                    </li>
                    <li>
                      Based on the positive results to date, the Company has
                      been enrolling children in the run-in for PROPEL3, the
                      Phase 3 registrational study, and expects to initiate
                      PROPEL3 by the end of 2023.
                    </li>
                    <li>
                      If approved, the Company believes that infigratinib has
                      the potential to capture a significant share of the market
                      based on blinded market research.
                    </li>
                    <li>
                      The Company is committed to exploring the potential of
                      infigratinib on the wider medical and functional impacts
                      of achondroplasia, hypochondroplasia and other skeletal
                      dysplasias, which hold significant unmet needs for
                      families.
                    </li>
                  </ul>
                </li>
                <li>
                  <strong
                    >BBP-418 – Glycosylation substrate for limb-girdle muscular
                    dystrophy type 2I/R9 (LGMD2I/R9):</strong
                  >
                  <ul type="circle">
                    <li>
                      In October 2023, the Company shared new long-term data
                      from its Phase 2 trial in patients with LGMD2I/R9 at the
                      Annual Congress of World Muscle Society. The new long-term
                      data remains consistent with earlier data from the Phase 2
                      study showing a well-tolerated safety profile and
                      encouraging preliminary efficacy. Additionally, early
                      changes in glycosylated αDG levels at 3 months predicted
                      ambulatory improvements at 9 months, providing support for
                      the possible use of glycosylated αDG levels as a surrogate
                      endpoint in the ongoing Phase 3 study for Accelerated
                      Approval by the FDA.
                    </li>
                    <li>
                      FORTIFY, the global Phase 3 registrational trial of
                      BBP-418, continues to enroll in the U.S. with clinical
                      trial sites planned for Europe and Australia. The Company
                      believes there is potential to pursue Accelerated Approval
                      for BBP-418 based on recent interactions with the FDA on
                      the use of glycosylated αDG levels as a surrogate
                      endpoint.
                    </li>
                    <li>
                      The Company believes BBP-418 has the potential to address
                      a population of 7,000 patients in the U.S. and Europe.
                    </li>
                    <li>
                      There are currently no disease-modifying treatments
                      available for LGMD2I/R9.
                    </li>
                  </ul>
                </li>
                <li>
                  <strong
                    >Encaleret – Calcium-sensing receptor (CaSR) inhibitor for
                    autosomal dominant hypocalcemia type 1 (ADH1):</strong
                  >
                  <ul type="circle">
                    <li>
                      In September 2023, the Company announced proof-of-concept
                      Phase 2b data evaluating the effects of encaleret on
                      mineral homeostasis in patients with ADH1 were published
                      in the <em>New England Journal of Medicine </em>in
                      partnership with the NIH. The results highlighted that
                      encaleret restored physiologic mineral homeostasis in 13
                      participants with ADH1, specifically correcting
                      hypocalcemia and reducing hypercalciuria.
                    </li>
                    <li>
                      Population genetics analyses estimate approximately 25,000
                      carriers of gain-of-function variants of the CaSR, the
                      underlying cause of ADH1, in the U.S. and European Union.
                    </li>
                    <li>
                      The Company has received approval to begin enrollment for
                      CALIBRATE, its Phase 3 clinical trial of encaleret, in
                      European Union and Japan, and anticipates sharing topline
                      data from CALIBRATE in 2024.
                    </li>
                    <li>
                      If approved, encaleret could be the first therapy
                      specifically indicated for the treatment of ADH1.
                    </li>
                  </ul>
                </li>
                <li>
                  <strong
                    >BBP-631 – AAV5 gene therapy candidate for congenital
                    adrenal hyperplasia (CAH):</strong
                  >
                  <ul type="circle">
                    <li>
                      The Phase 1/2 gene therapy trial of BBP-631 for CAH
                      continues to progress, with the dose-escalation portion of
                      the study (N=6) fully enrolled; the Company plans to share
                      data from the program in early 2024.
                    </li>
                    <li>
                      CAH is one of the most prevalent genetic diseases
                      potentially addressable with adeno-associated virus (AAV)
                      gene therapy, with more than 75,000 cases estimated in the
                      U.S. and European Union.
                    </li>
                  </ul>
                </li>
                <li>
                  <strong>RAS cancer portfolio:</strong>
                  <ul type="circle">
                    <li>
                      BBO-8520, an investigational, next-generation small
                      molecule direct KRAS<sup>G12C</sup>(ON) inhibitor
                      candidate that is designed to directly bind and inhibit
                      KRAS<sup>G12C</sup> in both its ON (GTP-bound) and OFF
                      (GDP-bound) conformations, remains on track to file an IND
                      in 2023.
                    </li>
                    <li>
                      The novel, direct KRAS (ON) targeting mechanism of
                      BBO-8520 was observed to be potentially superior to KRAS
                      (OFF) by data presented at the recent Triple Meeting,
                      suggesting scope for a potent, next-generation agent to
                      have an effect.
                    </li>
                    <li>
                      The Company’s PI3Kα:RAS breaker candidate BBO-10203 and
                      pan-KRAS program remain on track for an IND and a
                      development candidate selection, respectively, in 2024.
                    </li>
                  </ul>
                </li>
              </ul>
              <p><strong>Recent Corporate Updates:</strong></p>
              <ul type="disc">
                <li>
                  <strong
                    >Multi-year partnership with Resilience to advance BBP-631,
                    BBP-812 and future gene therapy treatments: </strong
                  >The Company and Resilience signed an agreement to transfer
                  the manufacturing process for the Company’s lead AAV-based
                  gene therapy candidates, BBP-631 and BBP-812, to Resilience’s
                  network of gene therapy manufacturing sites. Resilience will
                  also be the primary manufacturer for future clinical projects
                  across the Company’s gene therapy portfolio. The deal is
                  intended to reduce manufacturing costs, which have
                  historically accounted for approximately 50%-60% of the
                  Company’s gene therapy budget.
                </li>
                <li>
                  <strong
                    >$316 million gross proceeds raised between ATM and PIPE
                    financing:</strong
                  > The PIPE financing (as detailed in the forthcoming S-3
                  filing) included significant participation from four of the
                  largest investment management firms in the U.S., as well as a
                  number of large institutional investors and existing
                  investors.
                </li>
              </ul>
              <p><strong>Third Quarter 2023 Financial Results:</strong></p>
              <p>
                <strong
                  >Cash, Cash Equivalents, Marketable Securities and Short-Term
                  Restricted Cash</strong
                >
              </p>
              <p>
                Cash, cash equivalents and short-term restricted cash, totaled
                $521.9 million as of September 30, 2023, compared to cash, cash
                equivalents, marketable securities and short-term restricted
                cash of $466.2 million as of December 31, 2022. The net increase
                of $55.7 million in cash, cash equivalents, marketable
                securities and short-term restricted cash was primarily
                attributable to net proceeds received of $450.3 million from
                various equity financing offerings, and $5.2 million from stock
                option exercises, primarily offset by net cash used in operating
                activities of $402.9 million during the nine months ended
                September 30, 2023.
              </p>
              <p><strong>Revenue</strong></p>
              <p>
                Revenue for the three and nine months ended September 30, 2023
                was $4.1 million and $7.6 million, respectively, as compared to
                $0.3 million and $75.8 million for the same periods in the prior
                year, respectively. The net decrease of $68.2 million for the
                nine months ended September 30, 2023, compared to the same
                period in the prior year, was primarily attributable to the
                timing of revenue recognized from the Navire-BMS License
                Agreement which was entered into in May 2022.
              </p>
              <p><strong>Operating Costs and Expenses</strong></p>
              <p>
                Operating costs and expenses for the three and nine months ended
                September 30, 2023 were $161.8 million and $437.5 million,
                respectively, compared to $129.5 million and $458.7 million, for
                the same periods in the prior year, respectively.
              </p>
              <p>
                The overall increase of $32.3 million in operating costs and
                expenses for the three months ended September 30, 2023, compared
                to the same period in the prior year, was primarily due to an
                increase of $32.6 million in research and development and other
                expenses (R&amp;D) to advance the Company&#8217;s pipeline of
                development programs, an increase of $4.6 million in selling,
                general and administrative (SG&amp;A) expenses to support
                commercialization readiness efforts, offset by a decrease of
                $4.7 million in restructuring, impairment and related charges.
              </p>
              <p>
                The overall decrease of $21.2 million in operating costs and
                expenses for the nine months ended September 30, 2023, compared
                to the same period in the prior year, was primarily due to a
                decrease of $28.9 million in restructuring, impairment and
                related charges given that the majority of the restructuring
                initiatives occurred in the prior year, a decrease of $8.3
                million in SG&amp;A expenses as a result of restructuring
                initiatives, offset by an increase of $16.0 million in R&amp;D
                expenses to advance the Company&#8217;s pipeline of development
                programs.
              </p>
              <p>
                Restructuring, impairment and related charges for the three and
                nine months ended September 30, 2023, amounted to $0.3 million
                and $7.2 million, respectively. These charges primarily
                consisted of winding down, exit costs, and severance and
                employee-related costs. Restructuring, impairment and related
                charges for the same periods in the prior year were $5.0 million
                and $36.1 million, respectively. These charges primarily
                consisted of impairments and write-offs of long-lived assets,
                severance and employee-related costs, and exit and other related
                costs. The Company expects that the remaining restructuring,
                impairment and related charges will be immaterial through the
                end of 2023.
              </p>
              <p>
                Stock-based compensation expenses included in operating costs
                and expenses for the three months ended September 30, 2023 were
                $27.2 million, of which $14.1 million is included in R&amp;D
                expenses, and $13.1 million is included in SG&amp;A expenses.
                Stock-based compensation expenses included in operating costs
                and expenses for the three months ended September 30, 2022 were
                $18.7 million, of which $6.2 million is included in R&amp;D
                expenses, and $12.5 million is included in SG&amp;A expenses.
              </p>
              <p>
                Stock-based compensation expenses included in operating costs
                and expenses for the nine months ended September 30, 2023 were
                $77.9 million, of which $39.2 million is included in R&amp;D
                expenses, and $38.7 million is included in SG&amp;A expenses.
                Stock-based compensation expenses included in operating costs
                and expenses for the nine months ended September 30, 2022 were
                $71.2 million, of which $29.0 million is included in R&amp;D
                expenses, $41.0 million is included in SG&amp;A expenses, and
                $1.2 million is included in restructuring, impairment and
                related charges.
              </p>
              <p>
                “We were pleased to partner with leading institutional investors
                on our PIPE financing last quarter,” said Brian Stephenson,
                Ph.D., CFA, Chief Financial Officer of BridgeBio. “We continue
                to take advantage of our optionality in exploring less-dilutive
                forms of financing and anticipate that these, in conjunction
                with the PIPE financing, could capitalize us to profitability.”
              </p>
              <p>
                <img
                  fetchpriority="high"
                  decoding="async"
                  class="alignnone size-full wp-image-6128"
                  src="../../wp-content/uploads/2023/11/Q3-Graph-1.jpg"
                  alt=""
                  width="1384"
                  height="893"
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-1.jpeg          1384w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-1-300x194.jpeg   300w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-1-1024x661.jpeg 1024w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-1-768x496.jpeg   768w
                  "
                  sizes="(max-width: 1384px) 100vw, 1384px"
                />
              </p>
              <p>
                <img
                  decoding="async"
                  class="alignnone size-full wp-image-6123"
                  src="../../wp-content/uploads/2023/11/Q3-Graph-2.png"
                  alt=""
                  width="1396"
                  height="805"
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-2.png          1396w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-2-300x173.png   300w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-2-1024x590.png 1024w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-2-768x443.png   768w
                  "
                  sizes="(max-width: 1396px) 100vw, 1396px"
                />
              </p>
              <p data-wp-editing="1">
                <img
                  decoding="async"
                  class="alignnone size-full wp-image-6129"
                  src="../../wp-content/uploads/2023/11/Q3-third.jpg"
                  alt=""
                  width="1700"
                  height="2200"
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-third.jpg           1700w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-third-232x300.jpg    232w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-third-791x1024.jpg   791w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-third-768x994.jpg    768w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-third-1187x1536.jpg 1187w,
                    https://bridgebio.com/wp-content/uploads/2023/11/Q3-third-1583x2048.jpg 1583w
                  "
                  sizes="(max-width: 1700px) 100vw, 1700px"
                />
              </p>
              <div class="extended-table-container">
                <div class="table-wrap">
                  <img
                    decoding="async"
                    class="alignnone size-full wp-image-6127"
                    src="../../wp-content/uploads/2023/11/Q3-Graph-4-1.png"
                    alt=""
                    width="1348"
                    height="439"
                    srcset="
                      https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-4-1.png          1348w,
                      https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-4-1-300x98.png    300w,
                      https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-4-1-1024x333.png 1024w,
                      https://bridgebio.com/wp-content/uploads/2023/11/Q3-Graph-4-1-768x250.png   768w
                    "
                    sizes="(max-width: 1348px) 100vw, 1348px"
                  />
                </div>
              </div>
              <p>
                <strong>About BridgeBio Pharma, Inc.</strong><br />
                BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage
                biopharmaceutical company founded to discover, create, test, and
                deliver transformative medicines to treat patients who suffer
                from genetic diseases and cancers with clear genetic drivers.
                BridgeBio’s pipeline of development programs ranges from early
                science to advanced clinical trials. BridgeBio was founded in
                2015 and its team of experienced drug discoverers, developers
                and innovators are committed to applying advances in genetic
                medicine to help patients as quickly as possible. For more
                information visit <a
                  href="../../index.html"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong><u>bridgebiodev.wpengine.com</u></strong></a
                > and follow us on <a
                  href="https://www.linkedin.com/company/bridgebio/"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong><u>LinkedIn</u></strong></a
                > and <a
                  href="https://twitter.com/BridgeBioPharma"
                  target="_blank"
                  rel="nofollow noopener"
                  ><strong><u>Twitter</u></strong></a
                >.
              </p>
              <p>
                <strong
                  >BridgeBio Pharma, Inc. Forward-Looking Statements</strong
                >
              </p>
              <p>
                This press release contains forward-looking statements.
                Statements in this press release may include statements that are
                not historical facts and are considered forward-looking within
                the meaning of Section 27A of the Securities Act of 1933, as
                amended (the Securities Act), and Section 21E of the Securities
                Exchange Act of 1934, as amended (the Exchange Act), which are
                usually identified by the use of words such as “anticipates,”
                “believes,” “estimates,” “expects,” “intends,” “may,” “plans,”
                “projects,” “seeks,” “should,” “will,” “on track”, “remains” and
                variations of such words or similar expressions. We intend these
                forward-looking statements to be covered by the safe harbor
                provisions for forward-looking statements contained in Section
                27A of the Securities Act and Section 21E of the Exchange Act.
                These forward-looking statements, including statements relating
                to the clinical and therapeutic, market potential of our
                programs and product candidates, including the statement in Dr.
                Kumar’s quote regarding our data, pipeline and potential product
                launches; the timing and success of our clinical development
                programs, including the progress of our ongoing and planned
                clinical trials of acoramidis for patients with ATTR-CM, our
                plans to file an NDA for acoramidis with the FDA by the end of
                2023, and to file marketing authorization applications with
                additional regulatory authorities in 2024; the expected
                initiation of a Phase 3 clinical trial of infigratinib in
                children with achondroplasia by the end of 2023; the potential
                for glycosylated αDG to serve as a surrogate endpoint for
                Accelerated Approval in FORTIFY, the ongoing global phase 3
                trial registrational clinical trial of BBP-418 for LGMD2i, the
                plans of engaging with regulatory authorities, and the
                potentially-addressable population of BBP-418 in the United
                States and Europe; the potential of infigratinib for
                achondroplasia to have a potential of best-in-class efficacy
                with well-tolerated safety profile and to capture a significant
                share of the market based on blinded market research, if
                approved; the Company’s finding that ADH1 may be the most common
                presentation of nonsurgical hypoparathyroidism, the timing and
                status of Phase 3 CALIBRATE registrational trial of encaleret
                for ADH1, the timing of announcement of topline data from
                CALIBRATE in 2024, the estimated population of carriers of
                gain-of-function variants of the CaSR, the underlying cause of
                ADH1, in the U.S. and European Union, and the success of
                encaleret (if approved), including its potential to be the first
                therapy specifically indicated for the treatment of ADH1; the
                continuation and progress of our ongoing Phase 1/2 trial of
                BBP-631 for CAH, with plans to share data from the program in
                early 2024; the continued development, the timing, progression
                and success of the RAS franchise, including an IND application
                planned for <em>KRAS</em><sup><em>G12C </em></sup
                ><em>(ON) inhibitor BBO-8520 </em>in 2023, the intention to file
                an IND for PI3Kα:RAS breaker candidate BBO-10203 in 2024 and the
                planned development candidate selection for the pan-KRAS program
                in 2024; the success and anticipated cost reductions of our gene
                therapy manufacturing partnership with Resilience; potential
                financing activities and potential capitalization to
                profitability, reflect our current views about our plans,
                intentions, expectations and strategies, which are based on the
                information currently available to us and on assumptions we have
                made. Although we believe that our plans, intentions,
                expectations and strategies as reflected in or suggested by
                those forward-looking statements are reasonable, we can give no
                assurance that the plans, intentions, expectations or strategies
                will be attained or achieved. Furthermore, actual results may
                differ materially from those described in the forward-looking
                statements and will be affected by a number of risks,
                uncertainties and assumptions, including, but not limited to,
                initial and ongoing data from our preclinical studies and
                clinical trials not being indicative of final data, the
                potential size of the target patient populations our product
                candidates are designed to treat not being as large as
                anticipated, the design and success of ongoing and planned
                clinical trials, future regulatory filings, approvals and/or
                sales, despite having ongoing and future interactions with the
                FDA or other regulatory agencies to discuss potential paths to
                registration for our product candidates, the FDA or such other
                regulatory agencies not agreeing with our regulatory approval
                strategies, components of our filings, such as clinical trial
                designs, conduct and methodologies, or the sufficiency of data
                submitted, the continuing success of our collaborations, the
                Company’s ability to obtain additional funding, including
                through less dilutive sources of capital than equity financings,
                potential volatility in our share price, uncertainty regarding
                any impacts due to global health emergencies such as
                COVID-19,including delays in regulatory review, manufacturing
                and supply chain interruptions, adverse effects on healthcare
                systems and disruption of the global economy, the impacts of
                current macroeconomic and geopolitical events, including
                changing conditions from hostilities in Ukraine and in Israel
                and the Gaza Strip, increasing rates of inflation and rising
                interest rates, on business operations and expectations, as well
                as those risks set forth in the Risk Factors section of our
                Annual Report on Form 10-K for the year ended December 31, 2022
                and our other filings with the U.S. Securities and Exchange
                Commission. Moreover, we operate in a very competitive and
                rapidly changing environment in which new risks emerge from time
                to time. These forward-looking statements are based upon the
                current expectations and beliefs of our management as of the
                date of this press release, and are subject to certain risks and
                uncertainties that could cause actual results to differ
                materially from those described in the forward-looking
                statements. Except as required by applicable law, we assume no
                obligation to update publicly any forward-looking statements,
                whether as a result of new information, future events or
                otherwise.
              </p>
              <p>
                <strong>BridgeBio Contact:</strong><br />
                Vikram Bali<br />
                <a
                  href="../../cdn-cgi/l/email-protection.html#63000c0d170200172301110a070406010a0c0706154d1413060d040a0d064d000c0e"
                  ><span
                    class="__cf_email__"
                    data-cfemail="2c4f4342584d4f586c4e5e45484b494e454348495a025b5c49424b454249024f4341"
                    >[email&#160;protected]</span
                  ></a
                ><br />
                (650)-789-8220
              </p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4><a href="../index.html" class="red uppercase">News</a></h4>
            <small class="date">11.02.2023</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#dfb6b1b9b09fbdadb6bbb8babdb6b0f1bcb0b2"
              ><span
                class="__cf_email__"
                data-cfemail="f69f989099b694849f929193949f99d895999b"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
